



ISU ABXIS CO., LTD.

www.abxis.com/eng

ISU ABXIS is a biopharmaceutical company founded in 2001 with a desire of being an axis of therapeutic antibody as its names stands for ABXIS = AntiBody + aXIS. Beginning with the successful development and market launch of the Korean first therapeutic antibody Clotinab® in 2007, ISU ABXIS has established its own biotherapeutics development technologies and led Korean biopharmaceutical industry. ISU ABXIS will be dedicated to improving the lives of patients with cancers and incurable diseases.

Main Products



Therapeutic Area	Product	Generic Name	Major Market
Rare Disease	Abcertin®	Imiglucerase	Korea, Iran
	Fabagal®	Agalsidase beta	Korea
Cardiovascular	Clotinab®	Abciximab	Korea, Turkey

R&D Pipeline

Category	Project	Generic Name	Indication	Development Status				
				Discovery	Non-clinical	Phase 1	Phase 2	Phase 3
Novel	ISU104	-	ErbB3 positive cancers (head and neck, etc)	[Progress bar]				
	ISU304	Dalcinonacog alfa	Hemophilia B	[Progress bar]				
Bio-similar	ISU305	Eculizumab	Paroxysmal Nocturnal Hemoglobinuria	[Progress bar]				
	Abcertin®	Imiglucerase	Gaucher's Disease	[Progress bar]				
	ISU106	Nivolumab	Various Cancers	[Progress bar]				

CEO
Seok Joo Lee

Location
Global R&D Center Building
C 5th Fl, 22 Daewangpangyo-ro, 712 Beongil, Bundang-gu, Seongnam-si, Gyeonggi-do 13488

Specialty
1. Novel biological cancer drugs
2. Biosimilars in rare diseases

Tel / Fax / E-mail
T. 82-31-696-4700
F. 82-31-696-4690
E. abxis@isu.co.kr